Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.

Saad Z Usmani, MD FACP, Sarah Waheed, MD, Alan Mitchell, John Crowley, PhD, Antje Hoering, Nathan M Petty, Joshua Epstein, DSc, Christoph Heuck, MD, Shmuel Yaccoby, PhD, Donald Johann, MD, MS, Frits van Rhee, MD, PhD, Bart Barlogie, MD, Ph.D

Blood (2012) 120 (21): 2910.

https://doi.org/10.1182/blood.V120.21.2910.2910

Published: 2012

Journal Articles

Thrombin-Induced PARI Signaling Pathway Modulates ß-Catenin in the Transformation of Symptomatic Myeloma Cells Into the Quiescent Phenotype,

Erming Tian, PhD, Saad Usmani, MD, FACP, Yiming Zhou, PhD, Bart Barlogie, MD, Ph.D, John D Shaughnessy, Jr., PhD

Blood (2011) 118 (21): 3932.

https://doi.org/10.1182/blood.V118.21.3932.3932

Published: 2011

Journal Articles

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,

Saad Usmani, MD, FACP, Sarah Waheed, MD, Jackie Szymonifka, Susan Panozzo, Nathan M Petty, Doug Steward, Bijay Nair, MD, Yazan Alsayed, MD, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 3995.

https://doi.org/10.1182/blood.V118.21.3995.3995

Published: 2011

Journal Articles

Molecularly Classified High Risk Myeloma Cells with Low ROS Levels and High Nestin Expression Have High Proliferation Index and GEP80 Score,

Sarah K. Johnson, PhD, Yiming Zhou, PhD, Bart Barlogie, MD, Ph.D, John D Shaughnessy, Jr., PhD

Blood (2011) 118 (21): 3953.

https://doi.org/10.1182/blood.V118.21.3953.3953

Published: 2011

Journal Articles

A Better Mobilization Regimen for Newly Diagnosed Multiple Myeloma Patients,

Ahmed Y Abuabdou, MD, Eric R Rosenbaum, MD, MPH, Saad Usmani, MD, FACP, Bart Barlogie, MD, Ph.D, Michele Cottler-Fox, MD

Blood (2011) 118 (21): 4051.

https://doi.org/10.1182/blood.V118.21.4051.4051

Published: 2011

Journal Articles

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC)

Jeffrey Sawyer, Erming Tian, PhD, John D. Shaughnessy, Jr., PhD, Janet Lukacs, Regina Lichti Binz, Edward Thomas, Gael Sammartino, Charles Swanson, Christoph Heuck, MD, Yazan Alsayed, MD, Elias J. Anaissie, MD, Bijay Nair, MD, Sarah Waheed, MD, Saad Usmani, MD, FACP, Frits van Rhee, MD, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 298.

https://doi.org/10.1182/blood.V118.21.298.298

Published: 2011

Journal Articles

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

Saad Usmani, MD, FACP, Jackie Szymonifka, Rachael Sexton, Susan Panozzo, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, John Crowley, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 2947.

https://doi.org/10.1182/blood.V118.21.2947.2947

Published: 2011

Journal Articles

Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma

Tarun K. Garg, PhD, Junaid Khan, Susann Szmania, Amy D Greenway, Joshuah D Lingo, Amberly Moreno-Bost, Katie Stone, Antje Hoering, PhD, Emily Woods, Bijay Nair, MD, William Bellamy, PhD, Dario Campana, MD, PhD, Shmuel Yaccoby, PhD, Bart Barlogie, MD, Ph.D, Joshua Epstein, DSc, Frits van Rhee, MD, PhD

Blood (2011) 118 (21): 2918.

https://doi.org/10.1182/blood.V118.21.2918.2918

Published: 2011

Journal Articles

Loss of CYR61 in Myeloma Microenvironment Is Associated with Poor Survival

Sarah K. Johnson, PhD, Peter Stewart, PhD, Shmuel Yaccoby, PhD, Fenghuang Zhan, MD, PhD, Bart Barlogie, MD, Ph.D, John D Shaughnessy, Jr., PhD

Blood (2011) 118 (21): 1813.

https://doi.org/10.1182/blood.V118.21.1813.1813

Published: 2011

Journal Articles

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Sajjad Haider, MD, Lakshmikanth Katragadda, MD, Jameel Muzaffar, MD, Monica Grazziutti, MD, Muhammad R Akbar, MD, Michele H. Cottler-Fox, MD, Bart Barlogie, MD, Ph.D, Elias J. Anaissie, MD

Blood (2011) 118 (21): 4526.

https://doi.org/10.1182/blood.V118.21.4526.4526

Published: 2011

NARROW

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.

Thrombin-Induced PARI Signaling Pathway Modulates ß-Catenin in the Transformation of Symptomatic Myeloma Cells Into the Quiescent Phenotype,

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,

Molecularly Classified High Risk Myeloma Cells with Low ROS Levels and High Nestin Expression Have High Proliferation Index and GEP80 Score,

A Better Mobilization Regimen for Newly Diagnosed Multiple Myeloma Patients,

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC)

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma

Loss of CYR61 in Myeloma Microenvironment Is Associated with Poor Survival

The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only